English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

IT has been reported that malignant tumours elaborate a coagulative factor for their invasive growth (O'Meara and Jackson, 1958; O'Meara, 1958). Protamine sulphate has been found to inhibit the coagulative factor in vitro (Thornes and O'Meara, 1961) and protamine derivatives have been reported to inhibit the growth of human cancers (O'Meara and O'Halloran, 1963; Hughes, 1964; Lutton, 1964). The use of protamine derivatives in the treatment of malignant disease can cause side effects such as the transient nausea and lassitude noted by Hughes (1964) using prolothan G and prolothan P. During a clinical trial of these protamine derivatives another side effect became evident, namely tetany. This paper reports our findings of the effect of prolothan G and prolothan A on calcium metabolism.

The effect of protamine derivatives on calcium metabolism in patients with malignancy.